All In Biotech

Drug Trial Radar · NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

604

Planned (sponsor's estimate)

Start

Sep 7, 2023

Primary completion

Dec 31, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Advanced Solid Tumors

Interventions

  • RMC-9805Drug

    Oral Tablets

  • RMC-6236Drug

    Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Up to 3 years
  2. Dose Limiting ToxicitiesTime frame: 21 days

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Smilow Cancer Hospital (Yale University)

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Lee Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Recruiting

  • The Christ Hospital

    Cincinnati, Ohio · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas · Recruiting

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START

    San Antonio, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.